$EDIT
Editas Medicine, Inc.

2020 Q4 Form 10-K Financial Statement

#000155837021001915 Filed on February 26, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q2 2020 Q1
Revenue $11.42M $10.75M $5.723M
YoY Change -7.04% 361.33% 176.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $15.79M $14.08M $17.77M
YoY Change -6.68% -2.29% 1.6%
% of Gross Profit
Research & Development $61.50M $28.01M $34.57M
YoY Change 76.77% 18.85% 118.22%
% of Gross Profit
Depreciation & Amortization $1.180M $870.0K $798.0K
YoY Change 51.28% 26.09% 27.07%
% of Gross Profit
Operating Expenses $77.29M $42.09M $52.34M
YoY Change 49.48% 10.82% 57.03%
Operating Profit -$31.34M -$46.62M
YoY Change -12.09% 49.11%
Interest Expense $230.0K $590.0K $1.560M
YoY Change -86.06% -69.43% -24.27%
% of Operating Profit
Other Income/Expense, Net $3.375M $7.767M $8.892M
YoY Change 104.17% 316.91% 341.73%
Pretax Income -$62.50M -$23.57M -$37.72M
YoY Change 65.48% -30.25% 28.96%
Income Tax
% Of Pretax Income
Net Earnings -$62.50M -$23.57M -$37.72M
YoY Change 65.47% -30.23% 28.98%
Net Earnings / Revenue -547.32% -219.29% -659.16%
Basic Earnings Per Share -$1.00 -$0.43 -$0.69
Diluted Earnings Per Share -$1.00 -$0.43 -$0.69
COMMON SHARES
Basic Shares Outstanding 62.33M 55.35M 54.59M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $402.1M $1.085B $647.8M
YoY Change -42.47% 103.78% 89.37%
Cash & Equivalents $139.7M $485.8M $232.9M
Short-Term Investments $262.4M $598.7M $415.0M
Other Short-Term Assets $10.90M $9.500M $8.300M
YoY Change 73.02% 50.79% 66.0%
Inventory
Prepaid Expenses
Receivables $6.000M $1.900M $1.800M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $419.1M $610.1M $425.1M
YoY Change -9.65% 88.17% 22.47%
LONG-TERM ASSETS
Property, Plant & Equipment $14.02M $12.90M $12.22M
YoY Change 28.78% 51.17% -53.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $109.7M
YoY Change
Other Assets $4.703M $3.891M $2.391M
YoY Change -12.79% -27.65% -55.72%
Total Long-Term Assets $153.5M $45.36M $41.63M
YoY Change 240.83% 44.51% 30.92%
TOTAL ASSETS
Total Short-Term Assets $419.1M $610.1M $425.1M
Total Long-Term Assets $153.5M $45.36M $41.63M
Total Assets $572.6M $655.5M $466.7M
YoY Change 12.52% 84.32% 23.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.408M $6.339M $10.39M
YoY Change 9.67% 59.23% 57.48%
Accrued Expenses $24.05M $10.19M $8.669M
YoY Change 8.71% 24.79% -5.77%
Deferred Revenue $20.94M $40.94M $40.64M
YoY Change -10.93% -26.94%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $58.21M $68.15M $68.87M
YoY Change -2.93% -6.47% 67.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.50M $160.6M $1.000K
YoY Change 2749900.0% 16059900.0% -100.0%
Total Long-Term Liabilities $27.50M $160.6M $1.000K
YoY Change 2749900.0% 16059900.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $58.21M $68.15M $68.87M
Total Long-Term Liabilities $27.50M $160.6M $1.000K
Total Liabilities $179.0M $228.7M $232.2M
YoY Change -27.36% 40.69% 43.49%
SHAREHOLDERS EQUITY
Retained Earnings -$665.2M -$610.5M -$586.9M
YoY Change 21.12% 27.59%
Common Stock $1.059B $1.037B $820.8M
YoY Change 30.47% 54.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $393.6M $426.8M $234.6M
YoY Change
Total Liabilities & Shareholders Equity $572.6M $655.5M $466.7M
YoY Change 12.52% 84.32% 23.18%

Cashflow Statement

Concept 2020 Q4 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$62.50M -$23.57M -$37.72M
YoY Change 65.47% -30.23% 28.98%
Depreciation, Depletion And Amortization $1.180M $870.0K $798.0K
YoY Change 51.28% 26.09% 27.07%
Cash From Operating Activities -$40.10M -$30.85M -$54.09M
YoY Change -197.76% 19.53% 86.48%
INVESTING ACTIVITIES
Capital Expenditures -$1.370M -$1.840M $2.152M
YoY Change -18.93% 21.85% 199.72%
Acquisitions
YoY Change
Other Investing Activities -$107.5M $76.01M $48.62M
YoY Change -1230.6% -2.09% -5.3%
Cash From Investing Activities -$108.9M $74.18M $46.46M
YoY Change -1492.46% -2.54% -8.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $203.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.100M 211.1M 3.047M
YoY Change -89.24% 8809.28% 98.76%
NET CHANGE
Cash From Operating Activities -40.10M -30.85M -54.09M
Cash From Investing Activities -108.9M 74.18M 46.46M
Cash From Financing Activities 9.100M 211.1M 3.047M
Net Change In Cash -139.9M 254.5M -4.575M
YoY Change -204.87% 383.16% -119.76%
FREE CASH FLOW
Cash From Operating Activities -$40.10M -$30.85M -$54.09M
Capital Expenditures -$1.370M -$1.840M $2.152M
Free Cash Flow -$38.73M -$29.01M -$56.24M
YoY Change -190.68% 19.38% 89.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
CY2020 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001650664
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
us-gaap:ServiceMember
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-37687
CY2020 dei Entity Registrant Name
EntityRegistrantName
EDITAS MEDICINE, INC.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4097528
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
11 Hurley Street
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
CY2020 dei City Area Code
CityAreaCode
617
CY2020 dei Local Phone Number
LocalPhoneNumber
401-9000
CY2020 dei Security12b Title
Security12bTitle
Common Stock
CY2020 dei Trading Symbol
TradingSymbol
EDIT
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
1840064425
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67362791
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
139682000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
238183000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
262428000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
218957000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6048000
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
418000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10929000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6286000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
419087000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
463844000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
109664000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14020000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10887000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25128000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28761000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4703000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5393000
CY2020Q4 us-gaap Assets
Assets
572602000
CY2019Q4 us-gaap Assets
Assets
508885000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6408000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5843000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24046000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22120000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
20943000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
23514000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6811000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5804000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2682000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
58208000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
59963000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19324000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23277000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
73984000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
163207000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
27500000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1000
CY2020Q4 us-gaap Liabilities
Liabilities
179016000
CY2019Q4 us-gaap Liabilities
Liabilities
246448000
CY2019Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2020Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
195000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
195000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62689457
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54533798
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62563457
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54355798
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-665197000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1058823000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
811546000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-46000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
107000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-549221000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
393586000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
262437000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
572602000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
508885000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
90732000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20531000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31937000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
157996000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96898000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90654000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
67576000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
64555000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
55010000
CY2020 us-gaap Operating Expenses
OperatingExpenses
225572000
CY2019 us-gaap Operating Expenses
OperatingExpenses
161453000
CY2018 us-gaap Operating Expenses
OperatingExpenses
145664000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-134840000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-140922000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-113727000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
16259000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-137000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
328000
CY2020 us-gaap Investment Income Net
InvestmentIncomeNet
2605000
CY2019 us-gaap Investment Income Net
InvestmentIncomeNet
7313000
CY2018 us-gaap Investment Income Net
InvestmentIncomeNet
3445000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18864000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7176000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3773000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-115976000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-133746000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-109954000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-115976000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-133746000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-109954000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.98
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.68
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.33
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58609389
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49983329
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47097735
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-115976000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-133746000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-109954000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-153000
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
136000
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
47000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-116129000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-133610000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-109907000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
208080000
CY2018 edit Stock Issued During Period Value Repayment Of Notes
StockIssuedDuringPeriodValueRepaymentOfNotes
22030000
CY2018 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
1942000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10328000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26598000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
680000
CY2018 edit Stock Issued During Period Value Employee Restricted Common Stock Award Common Stock Subject To Repurchase
StockIssuedDuringPeriodValueEmployeeRestrictedCommonStockAwardCommonStockSubjectToRepurchase
4000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
47000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-109954000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
236162000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14863000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27243000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
620000
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
136000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-133746000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
262437000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19500000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
896000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
203726000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23156000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-153000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-115976000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
393586000
CY2020 us-gaap Profit Loss
ProfitLoss
-115976000
CY2019 us-gaap Profit Loss
ProfitLoss
-133746000
CY2018 us-gaap Profit Loss
ProfitLoss
-109954000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
23156000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
27243000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
26598000
CY2020 us-gaap Depreciation
Depreciation
3959000
CY2019 us-gaap Depreciation
Depreciation
2830000
CY2018 us-gaap Depreciation
Depreciation
3254000
CY2020 us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
16366000
CY2018 edit Noncash Investment In Equity Securities
NoncashInvestmentInEquitySecurities
3667000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-104000
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2928000
CY2018 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3268000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5630000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
388000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-649000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4643000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
495000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3410000
CY2020 edit Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-3633000
CY2019 edit Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
9300000
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
719000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
15000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
92000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
855000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
274000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1780000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1707000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
9485000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4042000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-91794000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
55395000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
22889000
CY2020 edit Increase Decrease In Right Of Use Liability
IncreaseDecreaseInRightOfUseLiability
-2946000
CY2019 edit Increase Decrease In Right Of Use Liability
IncreaseDecreaseInRightOfUseLiability
9324000
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2683000
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1652000
CY2018 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1030000
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
27500000
CY2018 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
14442000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-179843000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40669000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45707000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7162000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6167000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4754000
CY2020 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
12000
CY2019 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
102000
CY2018 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
37000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
458404000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
342183000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
459370000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
305000000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
360500000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
411000000
CY2020 edit Proceeds From Sale Of Equity Securities
ProceedsFromSaleOfEquitySecurities
20032000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-140522000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12252000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53087000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
203726000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
116341000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
76789000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19501000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14863000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10328000
CY2018 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
857000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
895000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
620000
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
680000
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Editas Medicine, Inc. (the “Company”) is a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The Company was incorporated in the state of Delaware in September 2013. Its principal offices are in Cambridge, Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising capital. The Company has primarily financed its operations through various equity financings, payments received under a research collaboration with Juno Therapeutics, a wholly-owned subsidiary of the Bristol-Myers Squibb Company (“Juno Therapeutics”), and payments received under a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited <span style="background-color:#ffffff;color:#212529;">(together with its affiliates, “Allergan”). </span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from pilot-scale manufacturing to large-scale production of products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In May 2020, the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”), under which the Company from time to time can issue and sell shares of its common stock through Cowen in at-the-market offerings for aggregate gross sale proceeds of up to $150.0 million ( the “ATM Facility”). As of December 31, 2020, the Company has not sold any shares of its common stock under the ATM Facility. In June 2020, the Company completed a public offering whereby the Company sold 6,900,000 shares of its common stock, inclusive of 900,000 shares of common stock sold by the Company pursuant to the full exercise of an option granted to the underwriters in connection with the offering and received net proceeds of approximately $203.7 million. As of December 31, 2020, the Company has raised an aggregate of $648.7 million in net proceeds through the sale of shares of its common stock in public offerings and at-the-market offerings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">The Company has incurred annual net operating losses in every year since its inception. The Company has an accumulated deficit of $665.2 million at December 31, 2020. The Company expects that its existing cash, cash equivalents and marketable securities</span> <span style="font-size:10pt;">on December 31, 2020, anticipated interest income, and the proceeds of its subsequent public offering described in Note 18, will enable it to fund its operating expenses and capital expenditure requirements for at least 36 months following the date of this Annual Report on Form 10-K. The Company will require substantial additional capital to fund its operations. The Company has never generated any product revenue. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate product revenue or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition.</span></p>
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
6900000
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
203700000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-665200000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
224122000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
131824000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
86940000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-96243000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
103407000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
239802000
CY2018 edit Stock Issued For Asset Acquisition
StockIssuedForAssetAcquisition
1942000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11854000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
239802000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136395000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148249000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143559000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136395000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
656000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
728000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
659000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
9760000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
5970000
CY2019 edit Non Cash Transactions Offering Cost Included In Accounts Payable And Accrued Expenses
NonCashTransactionsOfferingCostIncludedInAccountsPayableAndAccruedExpenses
15000
CY2018 edit Non Cash Transactions Offering Cost Included In Accounts Payable And Accrued Expenses
NonCashTransactionsOfferingCostIncludedInAccountsPayableAndAccruedExpenses
92000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
19461000
CY2018 edit Reclassification Of Liability For Founder Stock Repurchase
ReclassificationOfLiabilityForFounderStockRepurchase
4000
CY2018 edit Stock Issued For Settlement Of Notes Payable
StockIssuedForSettlementOfNotesPayable
22030000
CY2020 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on previously reported results of operations.</p>
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, accrued expenses, stock-based compensation expense, research and development expenses and deferred tax valuation allowances. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</p>
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4971000
CY2020Q4 edit Accrued Intellectual Property Fees
AccruedIntellectualPropertyFees
4240000
CY2019Q4 edit Accrued Intellectual Property Fees
AccruedIntellectualPropertyFees
3725000
CY2020Q4 edit Sublicensing Expenses
SublicensingExpenses
771000
CY2019Q4 edit Sublicensing Expenses
SublicensingExpenses
11416000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
3900000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
511774000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
238183000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3877000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1619000
CY2020Q4 edit Cash Cash Equivalents Restricted Cash Restricted Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsRestrictedCashRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale
515651000
CY2019Q4 edit Cash Cash Equivalents Restricted Cash Restricted Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsRestrictedCashRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale
239802000
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P30Y
CY2019Q4 edit Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
460700000
CY2019 edit Marketable Securities Unrealized Gain
MarketableSecuritiesUnrealizedGain
107000
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
460807000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
511820000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
18000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
64000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
511774000
CY2020Q4 edit Marketable Securities Noncurrent Number Of Securities
MarketableSecuritiesNoncurrentNumberOfSecurities
62
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
674000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
359000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
599000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24046000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22120000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
109700000
CY2020Q4 us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
16400000
CY2020 us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25115000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18091000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11095000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7204000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14020000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10887000
CY2020 us-gaap Depreciation
Depreciation
4000000.0
CY2019 us-gaap Depreciation
Depreciation
2800000
CY2018 us-gaap Depreciation
Depreciation
3300000
CY2020Q4 edit Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
12820000
CY2019Q4 edit Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
735000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5323000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
533000
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
700000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25128000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19461000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6811000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3848000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19324000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15909000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
10500000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
5600000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
1100000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
1000000.0
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1800000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8778000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9342000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7807000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3695000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
474000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
110000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
30206000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4071000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
26135000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1100000
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
418000
CY2020 edit Accounts Receivable Additions
AccountsReceivableAdditions
6097000
CY2020 edit Accounts Receivable Deductions
AccountsReceivableDeductions
467000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6048000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
186721000
CY2020 edit Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
508000
CY2020 edit Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
92302000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
94927000
CY2020Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
5767000
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
92302000
CY2020 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
60000
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12030284
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10433255
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23156000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27243000
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
2
CY2020 edit Defined Contribution Plan Maximum Annual Contributions Per Employee Matching Contribution Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeMatchingContributionAmount
6000
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0520
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0520
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.064
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0480
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0280
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.044
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.018
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.022
CY2018 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.007
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.001
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2910
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2670
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.324
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
70751000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
50511000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
19353000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
13767000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
11372000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
2219000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
46197000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
39070000
CY2020Q4 edit Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
7083000
CY2019Q4 edit Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
7879000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
25724000
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
31880000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5204000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
7865000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
185684000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
153191000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
178307000
CY2020Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3375000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
144540000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
7377000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
8651000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7377000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8651000
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
567000
CY2019Q4 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
859000
CY2020Q4 edit Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
6810000
CY2019Q4 edit Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
7792000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
75500000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
178300000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
144500000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
33800000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4811947
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4939699
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5723000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10749000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62841000
CY2020Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11419000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
52339000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
42088000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
53852000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
77293000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8892000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7767000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1170000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-37724000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-23572000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
7819000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-62499000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37724000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23572000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
7819000
CY2020Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-62499000
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2020Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.00
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2020Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.00
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2069000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2330000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3848000
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12284000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
33331000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
37979000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
38436000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
51707000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2013000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1863000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1647000
CY2019Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1653000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-29249000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-33786000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-32941000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-37770000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29249000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33786000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32941000
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37770000
CY2019Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.60
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.69
CY2019Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.66
CY2019Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.74

Files In Submission

Name View Source Status
0001558370-21-001915-index-headers.html Edgar Link pending
0001558370-21-001915-index.html Edgar Link pending
0001558370-21-001915.txt Edgar Link pending
0001558370-21-001915-xbrl.zip Edgar Link pending
edit-20201231.xsd Edgar Link pending
edit-20201231x10k.htm Edgar Link pending
edit-20201231x10k006.jpg Edgar Link pending
edit-20201231x10k007.jpg Edgar Link pending
edit-20201231x10k_htm.xml Edgar Link completed
edit-20201231xex10d13.htm Edgar Link pending
edit-20201231xex10d13001.jpg Edgar Link pending
edit-20201231xex10d14.htm Edgar Link pending
edit-20201231xex10d14001.jpg Edgar Link pending
edit-20201231xex10d18.htm Edgar Link pending
edit-20201231xex10d18002.jpg Edgar Link pending
edit-20201231xex10d24.htm Edgar Link pending
edit-20201231xex10d25.htm Edgar Link pending
edit-20201231xex10d32.htm Edgar Link pending
edit-20201231xex23d1.htm Edgar Link pending
edit-20201231xex31d1.htm Edgar Link pending
edit-20201231xex31d2.htm Edgar Link pending
edit-20201231xex32d1.htm Edgar Link pending
edit-20201231_cal.xml Edgar Link unprocessable
edit-20201231_def.xml Edgar Link unprocessable
edit-20201231_lab.xml Edgar Link unprocessable
edit-20201231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending